The 7th Annual Virtual BioHealth Capital Region Forum might be over, but that doesn’t mean you can’t access it again. Go to https://eventmobi.com/bhcrforum2021 now to watch or re-watch  every panel, keynote speaker, and bio byte video. Sessions include Fireside Chats with both Dr. Anthony Fauci, Director, U.S. National Institute of Allergy and Infectious Diseases, Joel Marcus, Executive Chairman and Founder, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments, and Dr. Tara Schwetz, Assistant Director for Biomedical Science Initiatives, White House Office of Science and Technology Policy (OSTP). Panels covering our forum theme of Big Bio….Big Data…. Converging range from Federal Funding, Real Estate, Developing Talent, and more.

Click here for the recap.

Read More

As a life sciences cluster, the BioHealth Capital Region is poised to become a top-three cluster in the Genetic Engineering & Biotechnology News (GEN) Top 10 Biopharma Clusters ranking on the strengths of early-stage companies becoming commercial successes and the construction of millions of square feet of new wet lab space.

For 2021, the BHCR held onto the fourth-place position behind New York/ New Jersey, San Francisco Bay Area, and the greater Boston area. The latest ranking was revealed at the seventh annual BioHealth Innovation Forum. The region held onto the coveted spot for multiple reasons, including significant funding from the National Institutes of Health, available wet lab space, and patent strength protecting intellectual property.

Read More

“Anyone who wants a COVID test can get one.” When that proclamation was made back in May 2020, it wasn’t true. There was a scarcity of testing supplies and limited sites, and it could take weeks to get back the results — making many of them essentially useless in clinical decision-making. The initial rapid tests on the market were a wild west of different companies who failed to ensure accuracy of their tests — -resulting in significant error rates.

Read More

• Emergent BioSolutions (NYSE:EBS) will manufacture doses of Providence Therapeutics' PTX-COVID19-B COVID-19 mRNA drug candidate under a five-year agreement. 
• The agreement is valued at $90M, and covers manufacturing services, studies to support global supply chain activities, and facility and equipment investments. 
• Next year, Emergent will manufacture tens of millions of doses of PTX-COVID19-B, as well as batches of PTX-COVID19-B formulated bulk drug substance that can yield hundreds of millions more doses.

Read More

Are you a biohealth start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Schedule your feedback session with BHI EIRs on one of the following dates. Pre-registration is required; Sign up here tinyurl.com/EIRfeedback

For questions/more information, contact BHI.

Read More

PASADENA, Calif., Sept. 10, 2021 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT and the first, longest-tenured and pioneering owner, operator and developer uniquely focused on collaborative life science, agtech and technology campuses in AAA innovation cluster locations, today announced that its executive chairman and founder, Joel S. Marcus, was honored last evening for Distinction in Civic Engagement and Renewal by the National September 11 Memorial & Museum during its Benefit Broadcast commemorating 20 years since 9/11. This prestigious recognition highlights Mr. Marcus's many meaningful contributions to the Memorial & Museum and his unwavering support of its mission to commemorate those who lost their lives in the terrorist attacks of September 11, 2001 and February 26, 1993; educate the public and a new generation about their ongoing global impact; and inspire Americans and people around the world to value courage, public service, hope, empathy and resilience in the face of adversity.

Read More

The debate over whether and how broadly to approve additional “booster” doses of COVID-19  vaccines is expected to play out this month. This much is certain: The FDA’s Vaccines and Related Biological Products Advisory Committee will discuss whether to recommend booster doses for the Pfizer/BioNTech COVID-19 vaccine (COMIRNATY®, BNT162b2) meets on September 17.

Read More

BETHESDA, Md., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced topline data from the Company’s study, conducted at the University of Maryland School of Medicine (UMSOM). The study, evaluating two lead Structurally Targeted Allosteric Regulators (STARs) compounds – GT-02287 and GT-02329 – for the treatment of Gaucher and GBA1 Parkinson’s Disease, demonstrated positive effects on all tested phenotypes.

Read More

IonQ, the leading developer of quantum computing devices, and the University of Maryland, an international powerhouse in quantum research and applications, today announced a partnership to create the National Quantum Lab at Maryland, or Q-Lab. It will be the nation’s first user facility that enables the scientific community to pursue world-leading research through hands-on access to a commercial-grade quantum computer. UMD-affiliated students, faculty, researchers, staff and partners across the country will have an unprecedented opportunity to gain experience with IonQ’s industry-leading trapped-ion quantum computer hardware and collaborate with IonQ scientists and engineers.

Read More

Rockville, MD, September 13, 2021 – The U.S. Pharmacopeia (USP) announces the launch of a new department, the Office of Organizational Culture, Equity and Inclusive Excellence (Equity Office). Headed by Chief Equity Officer (CEqO) and Senior Advisor to the CEO, Debra Joy Pérez, Ph.D. (she/her/ella), the Equity Office will shape and implement all diversity, equity, inclusion and belonging (DEIB) programs and initiatives. 

“Our DEIB work should always be about seeing diverse perspectives and how to approach complex problems from different viewpoints. DEIB is all about culture building, it is a way of looking at the work and the world that fosters the best workplace for our people,” said Debra Joy Pérez, Ph.D, USP CEqO and Senior Advisor to the CEO. “Evidence shows that when more diverse perspectives are included, there is more innovation, creative thinking and better problem solving—three critical drivers in applying our science to fulfill our public health mission. Our fundamental belief at USP is that equity equals excellence – excellence in our staff and excellence in our science. Only when we fully embrace the practice of equity can we benefit from the richness and talents of our staff.”  

Read More

Robert E. Fischell Institute for Biomedical Devices Director William Bentley was named the recipient of the 2021 Society for Biological Engineering D.I.C. Wang Award for Excellence in Biochemical Engineering. This annual award recognizes individuals for their contributions to the field and to the practice of biochemical engineering through their position in industry or academia as exemplified by Professor Daniel I.C. Wang of MIT. 

Wang made tremendous contributions to the biochemical engineering profession and biotechnology community, both in this country and internationally. He was a pivotal leader in developing the biotechnology industry and in shaping biochemical engineering education and training over the past five decades.

Read More

Most Detailed #Visualization of Human Cell Ever Created - this 3D model of a eukaryotic cell is created using X-ray, nuclear magnetic resonance (NMR), and cryo-electron microscopy datasets. It is an attempt to visualize the many pathways involved in cellular processes (i.e. signal transduction, protein synthesis, endocytosis, vesicular transport, cell-cell adhesion, apoptosis) as well as the great complexity & beauty of the cell’s molecular machinery.

Image: https://www.linkedin.com

Read More

At first blush, things are looking great in the life sciences real estate market. In particular, venture capital funding is exploding, supporting new companies or expansion from existing ones that should keep demand high for properties and continue to support larger rents. But this could lead to some overheating in the property market and to a shift in the way life sciences investors want to handle real estate.

Image: Unsplash - Life sciences lab space rents are soaring as biotech VC investment in the U.S. hits record levels.

Read More

his is how I see it…

We all have a choice. We all take in information. We use that information to make daily and life decisions. Some decisions affect only us, but most decisions affect us AND others.

We’ve learned throughout this pandemic that our decisions affect many others. I invite you to consider your decisions (vaccination, wearing masks when necessary, etc) and how you can help yourself AND even more importantly others. Consider it your service to others. Set aside political views and issues and serve others.

Read More

“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated. This week we welcome Bill Snider, Partner, BroadOak Capital Partners.

Bill Snider is a Partner at BroadOak and leads the firm’s growth capital investing activities. Mr. Snider has more than 25 years of institutional investment experience. Prior to BroadOak, he was a general partner and co-founder of Emerging Technology Partners (ETP), LLC, a life sciences-focused venture capital firm. Before ETP, Bill was a vice president and portfolio manager at T. Rowe Price, where his responsibilities included managing $2 billion of mutual fund and institutional client portfolios. He currently serves on the boards of Codex DNA, Halo Labs, Science and Medicine Group, and the MdBio Foundation. He has made more than 50 growth capital investments while at BroadOak and looks forward to making 50 more.

Read More